Wellbeing Digital Sciences Inc.

Equities

MEDI

CA94946J1084

Healthcare Facilities & Services

End-of-day quote NEO Exchange Other stock markets 23:00:00 03/04/2023 BST			5-day change	1st Jan Change
0.015 ^CAD	+200.00%		-.--%	-.--%

2023	Cardinal Group Companies LLC entered into an agreement to acquire KGK Science Inc. from Wellbeing Digital Sciences Inc. for $2 million.	CI
2023	Wellbeing Digital Sciences Inc.'s Wholly Owned Subsidiary KGK Sciences Inc Begins Recruitment in First-Of-Its-Kind Health Canada Approved Psilocybin Trial	CI

Wellbeing Digital Sciences Reports Sales Results for the Second Quarter of Fiscal 2022

March 18, 2022 at 05:23 pm

Wellbeing Digital Sciences reported sales results for the second quarter of fiscal 2022. The company sees second quarter revenue of CAD 1.7 million in first reporting period as it continues to grow mental wellness treatment clinics.

Latest news about Wellbeing Digital Sciences Inc.

Cardinal Group Companies LLC entered into an agreement to acquire KGK Science Inc. from Wellbeing Digital Sciences Inc. for $2 million.	15/06/23	CI
Wellbeing Digital Sciences Inc.'s Wholly Owned Subsidiary KGK Sciences Inc Begins Recruitment in First-Of-Its-Kind Health Canada Approved Psilocybin Trial	18/04/23	CI
KGK Science Inc. Awards an Institution Wide Cannabis Research License for Their New Facility by Health Canada	08/12/22	CI
Wellbeing Digital Sciences Inc. Appoints Mohammad Sharifi to Board of Directors	22/11/22	CI
Wellbeing Digital Sciences Inc. Announces Management Changes	18/11/22	CI
Nova Mentis Enters into Research Services Contract with KGK Science for Phase II A Clinical Trial	17/11/22	CI
Wellbeing Digital Signs LOI Manage Additional Clinics	04/10/22	CI
Wellbeing Digital Sciences Inc. Reports Earnings Results for the Full Year Ended July 31, 2022	13/09/22	CI
Wellbeing Digital Sciences Inc. Reports Earnings Results for the Fourth Quarter Ended July 31, 2022	13/09/22	CI
Wellbeing Digital Sciences Inc. Appoints Najla Guthrie to the Benzinga Psychedelic Advisory Council	30/08/22	CI
Wellbeing Digital Seeks Acquisitions	18/08/22	CI
Wellbeing Digital Sciences Inc. Announces Change of Financial Year End from July 31 to October 31	11/08/22	CI
Wellbeing Digital Sciences Appoints Natalie Dolphin as VP of Marketing and Investment Relations	21/06/22	CI
Wellbeing subsidiary KGK Science Announces Positive Clinical Trial Results of GJ 191 (JointAlive(R)) Supplementation in Treating OA	16/06/22	CI
Wellbeing Digital Sciences Announces the Appointment of Terry Zimaro as Chief Financial Officer	15/06/22	CI
Wellbeing Digital Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2022	15/06/22	CI
Wellbeing Digital Sciences Inc. Announces Resignation Joseph Ramelli as Chief Financial Officer	27/05/22	CI
Wellbeing Digital Sciences Inc. Appoints Michael Ho as the New Medical Director, Effective May 2, 2022	03/05/22	CI
Pathway Health Corp. (TSXV : PHC) entered into a memorandum of understanding to acquire Assets of Wellbeing Digital Sciences Inc and IRP Health Ltd	20/04/22	CI
Wellbeing Digital Sciences Reports Sales Results for the Second Quarter of Fiscal 2022	18/03/22	CI
Wellbeing Digital Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2022	16/03/22	CI
Wellbeing Digital Sciences Announces CEO Changes, Effective March 31, 2022	07/03/22	CI
Wellbeing Digital Sciences Inc Delivers its First IV Ketamine Treatment Under the Inpatient KITE Program	15/02/22	CI
KetamineOne Capital Limited has Changed its Name to Wellbeing Digital Sciences Inc	24/01/22	CI
Ketamine One Becomes Exclusive Ketamine Treatment Provider to Victoria Wellness	17/01/22	CI

Chart Wellbeing Digital Sciences Inc.

Duration

Period

More charts

Company Profile

Wellbeing Digital Sciences Inc. is a Canada-based mental healthcare company. The Company is focused on the development and implementation of clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. It operates through three segments: Wellbeing & IRP; KGK Science and Mindscape. It operates medical clinics across North America to help its patients access plant-based medicines, psychedelics, and other forms of mental health care, all of which have the potential to heal them of their physical and/or emotional pain. Its subsidiaries include Mindscape Ketamine & Infusions Therapy LLC, KGK Science Inc. and Integrated Rehab and Performance Ltd. It is also supported by a network of North American clinics that provide therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services with a focus on nutraceutical and emerging health care products.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
WELLBEING DIGITAL SCIENCES INC.	-.--%	1.79M
HCA HEALTHCARE, INC.	+18.63%	84.11B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+2.04%	27.25B
LABCORP HOLDINGS INC.	-10.34%	17.31B
FRESENIUS SE & CO. KGAA	-1.57%	16.83B
QUEST DIAGNOSTICS INCORPORATED	+3.37%	15.92B
REDE D'OR SÃO LUIZ S.A.	+1.50%	13.68B
NATERA, INC.	+73.12%	13.29B
TENET HEALTHCARE CORPORATION	+73.12%	12.73B
FRESENIUS MEDICAL CARE AG	+2.08%	12.62B

Other Healthcare Facilities & Services